# Virtue® SAB in the Treatment of Coronary ISR Trial

Study · id `cardio:ct-nct07045194` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07045194](<https://clinicaltrials.gov/study/NCT07045194>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07045194

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 740 participants.

## Technical summary

Registry record NCT07045194. Randomized; single masking; primary purpose treatment. Start 2025-10-20 (actual); primary completion 2028-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 740 participants (planned count; ClinicalTrials.gov record NCT07045194, source copy `cardio:ctgov-nct07045194-2026-10-22`, retrieved 2026-10-26)
- Started: 2025-10-20 (actual) (ClinicalTrials.gov record NCT07045194, source copy `cardio:ctgov-nct07045194-2026-10-22`, retrieved 2026-10-26)
- Primary completion: 2028-10 (anticipated) (ClinicalTrials.gov record NCT07045194, source copy `cardio:ctgov-nct07045194-2026-10-22`, retrieved 2026-10-26)
- Completion: 2032-10 (anticipated) (ClinicalTrials.gov record NCT07045194, source copy `cardio:ctgov-nct07045194-2026-10-22`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07045194, source copy `cardio:ctgov-nct07045194-2026-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07045194-2026-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Virtue® SAB in the Treatment of Coronary ISR Trial
- Condition: Coronary Artery Disease
- Intervention (Device): Virtue Sirolimus AngioInfusion Balloon
- Intervention (Device): AGENT™ Paclitaxel Drug-Coated Balloon
- Lead sponsor: Orchestra BioMed, Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: 332b01a1fb1198ed5e191a634ea8a09e0756410c86cd8c6dd3ce7bfb4df56b7c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
